Live feed16:05:00·1022dPRReleasevia QuantisnowCymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023ByQuantisnow·Wall Street's wire, on your screen.CBAY· CymaBay Therapeutics Inc.Health Care
